Crispr Therapeutics AG (CRSP) President Sells $607,407.90 in Stock

Crispr Therapeutics AG (NASDAQ:CRSP) President Rodger Novak sold 17,310 shares of Crispr Therapeutics stock in a transaction dated Tuesday, January 8th. The stock was sold at an average price of $35.09, for a total value of $607,407.90. Following the completion of the transaction, the president now owns 1,130,697 shares of the company’s stock, valued at $39,676,157.73. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Shares of CRSP stock opened at $35.15 on Friday. Crispr Therapeutics AG has a 52 week low of $22.22 and a 52 week high of $73.90. The company has a market capitalization of $1.91 billion, a price-to-earnings ratio of -20.56 and a beta of 3.48.

Crispr Therapeutics (NASDAQ:CRSP) last issued its earnings results on Thursday, November 8th. The company reported ($1.07) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.74) by ($0.33). Crispr Therapeutics had a negative net margin of 331.84% and a negative return on equity of 40.41%. The company had revenue of $0.56 million during the quarter, compared to analyst estimates of $2.64 million. During the same quarter in the previous year, the firm earned ($0.62) earnings per share. The business’s revenue was down 76.6% on a year-over-year basis. Equities research analysts predict that Crispr Therapeutics AG will post -3.26 EPS for the current year.

A number of research firms recently commented on CRSP. BidaskClub upgraded Crispr Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday. Zacks Investment Research downgraded Crispr Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, November 12th. SunTrust Banks reiterated a “buy” rating on shares of Crispr Therapeutics in a research note on Monday, December 31st. Needham & Company LLC began coverage on Crispr Therapeutics in a research note on Sunday, December 9th. They issued a “buy” rating and a $38.72 price target for the company. Finally, Wells Fargo & Co began coverage on Crispr Therapeutics in a research note on Wednesday, October 10th. They issued an “outperform” rating and a $65.00 price target for the company. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $59.19.

A number of hedge funds have recently modified their holdings of the business. Signaturefd LLC boosted its stake in Crispr Therapeutics by 123.8% in the second quarter. Signaturefd LLC now owns 2,350 shares of the company’s stock valued at $138,000 after acquiring an additional 1,300 shares during the period. Bank of America Corp DE boosted its stake in Crispr Therapeutics by 26.5% in the second quarter. Bank of America Corp DE now owns 9,407 shares of the company’s stock valued at $553,000 after acquiring an additional 1,972 shares during the period. TRUE Private Wealth Advisors acquired a new position in Crispr Therapeutics in the third quarter valued at approximately $122,000. Vanguard Group Inc. boosted its stake in Crispr Therapeutics by 6.6% in the third quarter. Vanguard Group Inc. now owns 52,023 shares of the company’s stock valued at $2,307,000 after acquiring an additional 3,200 shares during the period. Finally, Vanguard Group Inc boosted its position in shares of Crispr Therapeutics by 6.6% during the third quarter. Vanguard Group Inc now owns 52,023 shares of the company’s stock worth $2,307,000 after buying an additional 3,200 shares during the period. Institutional investors own 43.81% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Crispr Therapeutics AG (CRSP) President Sells $607,407.90 in Stock” was originally reported by WKRB News and is owned by of WKRB News. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at https://www.wkrb13.com/2019/01/12/crispr-therapeutics-ag-crsp-president-sells-607407-90-in-stock.html.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.

Further Reading: Cost of Debt

Insider Buying and Selling by Quarter for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply